 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EMS stock settled at Rs 279.75, with volume of 18.2 lakh shares on the BSE.

EMS settles 33% higher on debut despite bears controlling Dalal Street

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 910 in its research report dated August 08, 2023.

Buy Eris Lifesciences; target of Rs 910: Prabhudas Lilladher

Eris Life Consolidated June 2023 Net Sales at Rs 466.62 crore, up 17.07% Y-o-Y

Promoter Padmaja Gangireddy has sold 12.5 lakh equity shares or 1.76 percent stake in Spandana Sphoorty Financial at an average price of Rs 830.15 per share.

Societe Generale buys Bandhan Bank shares worth Rs 382 crore, Goldman Sachs picks 1.2% stake in Spandana Sphoorty

A series of value accretive acquisitions in the dermatology space have improved prospects for the drugmaker

Eris Lifesciences gets thumbs up from analysts on pure-domestic play, foray into dermatology

Rekha Jhunjhunwala, the widow of the late Rakesh Jhunjhunwala, has sold 5.5 percent stake in Rallis India.

Clarios ARBL Holding exits Amara Raja, Rekha Jhunjhunwala offloads 5.5% stake in Rallis India

The stake sale by Small Cap World Fund and New World Fund was worth Rs 551.03 crore.

Bulk Deals: Small Cap World Fund, New World Fund exit Piramal Enterprises

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 780 in its research report dated May 18, 2023.

Buy Eris Lifesciences; target of Rs 780: Prabhudas Lilladher

Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 720 in its research report dated May 17, 2023.

Buy Eris Lifesciences; target of Rs 720: Motilal Oswal

Eris Life Standalone March 2023 Net Sales at Rs 314.58 crore, up 11.5% Y-o-Y

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Watchers	17
52-Wk Low	551.30
52-Wk High	880.00

Market Cap	112.93B
Volume (M)	237,713.00
52-Wk High	880.00
52-Wk Low	551.30

ERIS.NSE Eris Lifesciences Ltd.

About

Feed

News

Fundamentals